Clinical trial · Interventional
Comparative Study of Long-acting and Short Acting Triptorelin in PCOS Patients Who Underwent IVF/ICSI
Comparative Study of Long-acting and Short Acting Triptorelin on Pituitary Down-regulation in Long Protocol in PCOS Patients Who Underwent IVF/ICSI Treatment
NCT02477566CI-TRIAL-00018338unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To test whether long-acting Triptorelin on pituitary down-regulation can improve the clinical pregnancy rate and reduces the incidence of ovarian hyperstimulation syndrome (OHSS) in infertile high-risk patients with polycystic ovaries (PCOs) who underwent in vitro fertilization (IVF) or Intracytoplasmic sperm injection
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| In Vitro Fertilization | — | UNRESOLVED | — |
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Long-acting Triptorelin | Drug | — | UNRESOLVED |
| Short-acting Triptorelin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Long-acting Triptorelin
- description
- Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal
- interventionNames
- Drug: Long-acting Triptorelin
- type
- ACTIVE_COMPARATOR
- label
- Short-acting Triptorelin
- description
- Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2\<40pg/ml in serum, was initiated during the luteal phase
- interventionNames
- Drug: Short-acting Triptorelin
Primary outcomes (1)
- measure
- Clinical pregnancy rate
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 22 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * PCOS patients diagnosis by Rotterdam Consensus on Diagnostic Criteria who underwent IVF/ICSI treatment Exclusion Criteria: * Patients with poor ovarian reserve, * immunological disease, * endometriosis, * uterine abnormality, * endometrium thickness \< 8mm before embryo transfer, * fewer than two good-quality embryos available for transfer or patients with inadequate data for analysis were excluded.
References
Publications (0)
Data not yet available
No reference posted for this study.